Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Compound made by gut bacteria from ellagitannins in pomegranate and walnuts, and sold ready-made (for example Mitopure) because not everyone's gut bacteria produce it. Trials show it changes mitochondrial and inflammation markers in people; effects on muscle strength and endurance are mixed, and the two main trials in middle-aged and older adults missed their primary endpoints.
2 of 2 results reported a benefit, from 1 published study.
1 randomised trial, 50 people
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultFrequent illness, weak immune response, slow recovery from infections.
Also known as: UA, Mitopure
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Urolithin A in immune support.
Study designs behind these findings.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 41174221 2025 | Randomised trial | 50 | 4 weeks | CD8+ fatty acid oxidation capacity | 14.72 percentage points (95% confidence interval (CI) = 6.46 to 22.99; P = 0.0061) | Benefit |
| PMID 41174221 2025 | Randomised trial | 50 | 4 weeks | peripheral naive-like, less terminally exhausted CD8+ cells | 0.50 percentage points (95% CI = 0.16 to 0.83; P = 0.0437) | Benefit |
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysisPetrelli F, et al. · Urologic oncology · 2026PMID 40935764 ↗02Clinical benefits and risks of high-dose intravenous vitamin C: a systematic reviewAlangari A, et al. · Journal of medicine and life · 2026PMID 41815850 ↗03Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026Weiss SL, et al. · Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2026PMID 41869844 ↗04Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026Weiss SL, et al. · Intensive care medicine · 2026PMID 41870559 ↗Be the first to share what you noticed with Urolithin A for immune support. Why counts start empty.